<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00220168</url>
  </required_header>
  <id_info>
    <org_study_id>2166</org_study_id>
    <nct_id>NCT00220168</nct_id>
  </id_info>
  <brief_title>Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours</brief_title>
  <official_title>A Phase II Trial Evaluating Irinotecan and Capecitabine in Patients With Relapsed/Refractory Upper Gastrointestinal Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the efficacy and toxicity of a 3 weekly regimen&#xD;
      containing irinotecan combined with capecitabine in the setting of relapsed or refractory&#xD;
      upper gastrointestinal tumours. Patients with locally advanced or metastatic adenocarcinoma&#xD;
      or squamous cell carcinoma originating from the oesophagus, oesophagogastric junction or&#xD;
      stomach who have previously received chemotherapy and have either failed to respond or who&#xD;
      have relapsed within 3 months after an initial response will be eligible for treatment in&#xD;
      this study.&#xD;
&#xD;
      The response rate, failure-free survival and overall survival of treated patients will be&#xD;
      evaluated. Toxicity and quality of life will also be monitored closely.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rates</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to disease progression (TTP)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (incidence of febrile neutropenia, in-patient admissions, severity of diarrhea, mucositis, aesthesia, transfusion requirements).</measure>
  </secondary_outcome>
  <enrollment type="Actual">33</enrollment>
  <condition>Upper Gastrointestinal Tumours</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan, Capecitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven adenocarcinoma or squamous cell carcinoma of oesophagus, O-G&#xD;
             junction and stomach, not amenable to surgical resection.&#xD;
&#xD;
          -  Bidimensionally measurable disease, or unidimensional measurable disease assessable by&#xD;
             CT scanning, not within previously irradiated areas.&#xD;
&#xD;
          -  Patients with progressive disease during previous chemotherapy treatment or within&#xD;
             three months of stopping treatment.&#xD;
&#xD;
          -  At least one previous chemotherapy regimen, given within 3 months prior to inclusion&#xD;
             in this study.&#xD;
&#xD;
          -  No previous exposure to irinotecan.&#xD;
&#xD;
          -  Adequate bone marrow function with platelets &gt;100 X 109/L; WBC &gt; 3 X 109/L;&#xD;
             Neutrophils &gt; 1.5 X 109/L at the time of study entry.&#xD;
&#xD;
          -  Satisfactory renal function. Creatinine clearance (measured by Cockcroft and Gault)&#xD;
             &gt;50ml/min and Cr &lt;135.&#xD;
&#xD;
          -  Satisfactory liver function:&#xD;
&#xD;
          -  In the absence of liver metastases: Bilirubin &lt; 1.25N (N=upper limit of normal range)&#xD;
             Hepatic transaminases &lt; 2.5N Prothrombin time &lt; 1.5N&#xD;
&#xD;
          -  In the presence of liver metastases: Bilirubin &lt; 1.5N Hepatic transaminases &lt; 5N&#xD;
             Prothrombin time &lt; 1.5N&#xD;
&#xD;
          -  No uncontrolled medical condition&#xD;
&#xD;
          -  No previous malignant disease except for non-melanotic skin cancer or in-situ&#xD;
             carcinoma of the uterine cervix.&#xD;
&#xD;
          -  ECOG performance status of 0, 1 or 2.&#xD;
&#xD;
          -  Predicted life expectancy of &gt; 3 months.&#xD;
&#xD;
          -  Adequate contraceptive precautions&#xD;
&#xD;
          -  Informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical or psychiatric conditions resulting in inability of patient to give written&#xD;
             consent.&#xD;
&#xD;
          -  ECOG Performance status &gt;2&#xD;
&#xD;
          -  Intracerebral metastases or meningeal carcinomatosis&#xD;
&#xD;
          -  Unresolved bowel obstruction&#xD;
&#xD;
          -  Creatinine clearance &lt;50ml/min, Cr &gt;135&#xD;
&#xD;
          -  Uncontrolled angina pectoris, heart failure (New York heart classification 3 or 4).&#xD;
&#xD;
          -  Pregnancy/lactation&#xD;
&#xD;
          -  Previous malignancy other than adequately treated basal cell carcinoma of the skin or&#xD;
             cervical carcinoma in situ.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cunningham</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>September 19, 2005</study_first_submitted>
  <study_first_submitted_qc>September 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>December 15, 2009</last_update_submitted>
  <last_update_submitted_qc>December 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jane Lawrence</name_title>
    <organization>Royal Marsden NHS Foundation Trust</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digestive System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

